- |||||||||| Review, Journal: Claudin 1, 4, 6 and 18 isoform 2 as targets for the treatment of cancer (Review). (Pubmed Central) - Sep 21, 2024
In addition, bsAbs, CAR T cells and their derivatives targeting CLDN4, 6 or 18.2 are in phase I and/or II clinical trials. AZD0901, IBI343, zolbetuximab and the anti?CLDN1 mAb ALE.C04 have been granted fast track designation or priority review designation by the US Food and Drug Administration.
- |||||||||| ALE.C04 / Alentis Therap
Enrollment open, Metastases: Study of ALE.C04 in Patients With Head and Neck Cancer (clinicaltrials.gov) - Nov 22, 2023
P1/2, N=220, Recruiting,
AZD0901, IBI343, zolbetuximab and the anti?CLDN1 mAb ALE.C04 have been granted fast track designation or priority review designation by the US Food and Drug Administration. Not yet recruiting --> Recruiting
- |||||||||| ALE.C04 / Alentis Therap
CLAUDIN-1 targeting antibody ALE.C04 drives single activity and restores anti-PD1 efficacy in solid tumors (Section 36; Poster Board #18) - Mar 14, 2023 - Abstract #AACR2023AACR_6767;
ALE.C04 perturbs the interface between CLDN1+ tumor cells and the stroma, thus restoring immune cell infiltration. Our pre-clinical data showed that: i) NJ-CLDN1 is a novel and druggable target in solid tumors ii) ALE.C04 is a selective anti-CLDN1 antibody capable of driving anti-tumor activity as both single agent and in combination with anti-PD1.
|
